Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase 4 2Phase NA 1Phase 2/3 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 14Breast 7Myeloid 6Thoracic 5Gynecologic 3Genitourinary 3Dermatologic 3Classical hematology 3Plasma cell 2Head & Neck 2CNS 2Tumor-Agnostic 1Other neoplasm 1Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 2Venous Thromboembolism 1Testicular Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Aspirin × Genitourinary × Clear all
NCT03899987 2026-05-05

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Roswell Park Cancer Institute

Phase 2 Active not recruiting
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT06866964 2026-02-02

ASPIRE

Wake Forest University Health Sciences

Phase 2 Recruiting
35 enrolled
Classical hematologyGenitourinary

Neoplasms, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Venous Thromboembolism

NCT02420652 2023-02-08

PRIMA

Rutgers, The State University of New Jersey

Phase 2 Terminated
27 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡